The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018
Summary Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expect...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2022-03, Vol.196 (5), p.1219-1224 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1224 |
|---|---|
| container_issue | 5 |
| container_start_page | 1219 |
| container_title | British journal of haematology |
| container_volume | 196 |
| creator | Maas, Carolien C. H. M. Klaveren, David Ector, Geneviève I. C. G. Posthuma, Eduardus F. M. Visser, Otto Westerweel, Peter E. Janssen, Jeroen J. W. M. Blijlevens, Nicole M. A. Dinmohamed, Avinash G. |
| description | Summary
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near‐normal life expectancy in a modern TKI era. |
| doi_str_mv | 10.1111/bjh.17989 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2632054329</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-ccf19364365bc54e3709ad58cdb9ba2a15f6d7cb7c7300e107df23099790150d3</originalsourceid><addsrcrecordid>eNp1kc9qFTEUh4Mo9lpd-AIScKPgtCeT-RcXgha1StFNXYdMknFyzUzGZKb17voIQt-wT-K5vbWoYBZJSD6-cw4_Qh4zOGC4Dtt1f8Bq0Yg7ZMV4VWY5K9hdsgKAOmNQNHvkQUprAMahZPfJHi-aqsxztiKXp72l9iz4ZXZhpKGjMz74kNL27l2Hvz8mq2c16g11I53U7Ow4J3ru5p7qPobRaTpsrA_OUG-Xb8oOTr2kik5hWrzaeq8ufrYqWUPTvJhrzbbKJ4t79Go06QVl2P7VxWUOrHlI7nXKJ_vo5twnX969PT06zk4-v_9w9Pok00XBRaZ1xwSvChy41WVheQ1CmbLRphWtyhUru8rUuq11zQEsg9p0OQchagGsBMP3yaudd1rawRqNY0Xl5RTdoOJGBuXk3z-j6-XXcCYF-hhUKHh2I4jh-2LTLAeXtPU4kg1LknkFWJrXBUf06T_oOixxxPGQ4jmUBc8FUs93lI6YQLTdbTMM5DZqiVHL66iRffJn97fk72wRONwB587bzf9N8s3H453yF3-Btbk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2632054329</pqid></control><display><type>article</type><title>The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Maas, Carolien C. H. M. ; Klaveren, David ; Ector, Geneviève I. C. G. ; Posthuma, Eduardus F. M. ; Visser, Otto ; Westerweel, Peter E. ; Janssen, Jeroen J. W. M. ; Blijlevens, Nicole M. A. ; Dinmohamed, Avinash G.</creator><creatorcontrib>Maas, Carolien C. H. M. ; Klaveren, David ; Ector, Geneviève I. C. G. ; Posthuma, Eduardus F. M. ; Visser, Otto ; Westerweel, Peter E. ; Janssen, Jeroen J. W. M. ; Blijlevens, Nicole M. A. ; Dinmohamed, Avinash G.</creatorcontrib><description>Summary
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near‐normal life expectancy in a modern TKI era.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.17989</identifier><identifier>PMID: 34865221</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; chronic myeloid leukaemia ; Chronic myeloid leukemia ; epidemiology ; Female ; Haematological malignancy–Clinical ; Hematology ; Humans ; imatinib ; leukaemia ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology ; Life Expectancy ; Life span ; Male ; mathematical modelling ; Middle Aged ; Netherlands - epidemiology ; Population studies ; Population-based studies ; Protein Kinase Inhibitors - therapeutic use ; Protein-tyrosine kinase ; Short Report ; Survival Analysis</subject><ispartof>British journal of haematology, 2022-03, Vol.196 (5), p.1219-1224</ispartof><rights>2021 The Authors. published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-ccf19364365bc54e3709ad58cdb9ba2a15f6d7cb7c7300e107df23099790150d3</citedby><cites>FETCH-LOGICAL-c4439-ccf19364365bc54e3709ad58cdb9ba2a15f6d7cb7c7300e107df23099790150d3</cites><orcidid>0000-0002-2096-606X ; 0000-0002-3867-2465 ; 0000-0002-1558-944X ; 0000-0002-4767-6716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.17989$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.17989$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27903,27904,45553,45554,46388,46812</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34865221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maas, Carolien C. H. M.</creatorcontrib><creatorcontrib>Klaveren, David</creatorcontrib><creatorcontrib>Ector, Geneviève I. C. G.</creatorcontrib><creatorcontrib>Posthuma, Eduardus F. M.</creatorcontrib><creatorcontrib>Visser, Otto</creatorcontrib><creatorcontrib>Westerweel, Peter E.</creatorcontrib><creatorcontrib>Janssen, Jeroen J. W. M.</creatorcontrib><creatorcontrib>Blijlevens, Nicole M. A.</creatorcontrib><creatorcontrib>Dinmohamed, Avinash G.</creatorcontrib><title>The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near‐normal life expectancy in a modern TKI era.</description><subject>Adult</subject><subject>chronic myeloid leukaemia</subject><subject>Chronic myeloid leukemia</subject><subject>epidemiology</subject><subject>Female</subject><subject>Haematological malignancy–Clinical</subject><subject>Hematology</subject><subject>Humans</subject><subject>imatinib</subject><subject>leukaemia</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</subject><subject>Life Expectancy</subject><subject>Life span</subject><subject>Male</subject><subject>mathematical modelling</subject><subject>Middle Aged</subject><subject>Netherlands - epidemiology</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Protein-tyrosine kinase</subject><subject>Short Report</subject><subject>Survival Analysis</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc9qFTEUh4Mo9lpd-AIScKPgtCeT-RcXgha1StFNXYdMknFyzUzGZKb17voIQt-wT-K5vbWoYBZJSD6-cw4_Qh4zOGC4Dtt1f8Bq0Yg7ZMV4VWY5K9hdsgKAOmNQNHvkQUprAMahZPfJHi-aqsxztiKXp72l9iz4ZXZhpKGjMz74kNL27l2Hvz8mq2c16g11I53U7Ow4J3ru5p7qPobRaTpsrA_OUG-Xb8oOTr2kik5hWrzaeq8ufrYqWUPTvJhrzbbKJ4t79Go06QVl2P7VxWUOrHlI7nXKJ_vo5twnX969PT06zk4-v_9w9Pok00XBRaZ1xwSvChy41WVheQ1CmbLRphWtyhUru8rUuq11zQEsg9p0OQchagGsBMP3yaudd1rawRqNY0Xl5RTdoOJGBuXk3z-j6-XXcCYF-hhUKHh2I4jh-2LTLAeXtPU4kg1LknkFWJrXBUf06T_oOixxxPGQ4jmUBc8FUs93lI6YQLTdbTMM5DZqiVHL66iRffJn97fk72wRONwB587bzf9N8s3H453yF3-Btbk</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Maas, Carolien C. H. M.</creator><creator>Klaveren, David</creator><creator>Ector, Geneviève I. C. G.</creator><creator>Posthuma, Eduardus F. M.</creator><creator>Visser, Otto</creator><creator>Westerweel, Peter E.</creator><creator>Janssen, Jeroen J. W. M.</creator><creator>Blijlevens, Nicole M. A.</creator><creator>Dinmohamed, Avinash G.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2096-606X</orcidid><orcidid>https://orcid.org/0000-0002-3867-2465</orcidid><orcidid>https://orcid.org/0000-0002-1558-944X</orcidid><orcidid>https://orcid.org/0000-0002-4767-6716</orcidid></search><sort><creationdate>202203</creationdate><title>The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018</title><author>Maas, Carolien C. H. M. ; Klaveren, David ; Ector, Geneviève I. C. G. ; Posthuma, Eduardus F. M. ; Visser, Otto ; Westerweel, Peter E. ; Janssen, Jeroen J. W. M. ; Blijlevens, Nicole M. A. ; Dinmohamed, Avinash G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-ccf19364365bc54e3709ad58cdb9ba2a15f6d7cb7c7300e107df23099790150d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>chronic myeloid leukaemia</topic><topic>Chronic myeloid leukemia</topic><topic>epidemiology</topic><topic>Female</topic><topic>Haematological malignancy–Clinical</topic><topic>Hematology</topic><topic>Humans</topic><topic>imatinib</topic><topic>leukaemia</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology</topic><topic>Life Expectancy</topic><topic>Life span</topic><topic>Male</topic><topic>mathematical modelling</topic><topic>Middle Aged</topic><topic>Netherlands - epidemiology</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Protein-tyrosine kinase</topic><topic>Short Report</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maas, Carolien C. H. M.</creatorcontrib><creatorcontrib>Klaveren, David</creatorcontrib><creatorcontrib>Ector, Geneviève I. C. G.</creatorcontrib><creatorcontrib>Posthuma, Eduardus F. M.</creatorcontrib><creatorcontrib>Visser, Otto</creatorcontrib><creatorcontrib>Westerweel, Peter E.</creatorcontrib><creatorcontrib>Janssen, Jeroen J. W. M.</creatorcontrib><creatorcontrib>Blijlevens, Nicole M. A.</creatorcontrib><creatorcontrib>Dinmohamed, Avinash G.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maas, Carolien C. H. M.</au><au>Klaveren, David</au><au>Ector, Geneviève I. C. G.</au><au>Posthuma, Eduardus F. M.</au><au>Visser, Otto</au><au>Westerweel, Peter E.</au><au>Janssen, Jeroen J. W. M.</au><au>Blijlevens, Nicole M. A.</au><au>Dinmohamed, Avinash G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2022-03</date><risdate>2022</risdate><volume>196</volume><issue>5</issue><spage>1219</spage><epage>1224</epage><pages>1219-1224</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer Registry, we examined the life expectancy of patients with CML in the Netherlands diagnosed during 1989–2018. As of the early 2010s, the life expectancy of patients with CML who survived several years after diagnosis came narrowly close to the general population’s life expectancy, regardless of age. This finding can essentially be ascribed to the introduction and broader application of tyrosine kinase inhibitors (TKIs) and provide optimism to patients with CML who can look forward to a near‐normal life expectancy in a modern TKI era.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34865221</pmid><doi>10.1111/bjh.17989</doi><tpages>1224</tpages><orcidid>https://orcid.org/0000-0002-2096-606X</orcidid><orcidid>https://orcid.org/0000-0002-3867-2465</orcidid><orcidid>https://orcid.org/0000-0002-1558-944X</orcidid><orcidid>https://orcid.org/0000-0002-4767-6716</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2022-03, Vol.196 (5), p.1219-1224 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9300106 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content |
| subjects | Adult chronic myeloid leukaemia Chronic myeloid leukemia epidemiology Female Haematological malignancy–Clinical Hematology Humans imatinib leukaemia Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology Life Expectancy Life span Male mathematical modelling Middle Aged Netherlands - epidemiology Population studies Population-based studies Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Short Report Survival Analysis |
| title | The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T05%3A23%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20evolution%20of%20the%20loss%20of%20life%20expectancy%20in%20patients%20with%20chronic%20myeloid%20leukaemia:%20a%20population%E2%80%90based%20study%20in%20the%20Netherlands,%201989%E2%80%932018&rft.jtitle=British%20journal%20of%20haematology&rft.au=Maas,%20Carolien%20C.%20H.%20M.&rft.date=2022-03&rft.volume=196&rft.issue=5&rft.spage=1219&rft.epage=1224&rft.pages=1219-1224&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.17989&rft_dat=%3Cproquest_pubme%3E2632054329%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2632054329&rft_id=info:pmid/34865221&rfr_iscdi=true |